title: Recombinant proapoA-I(Lys107del) shows impaired lipid binding associated with reduced binding to plasma high density lipoprotein.
abstract: In the present study apoA-I (Lys 107del), a naturally occurring human apoA-I variant with a deletion of Lys 107, was expressed in E. coli to examine the effect of this mutation on lipid binding, cholesterol efflux and lecithin:cholesterol acyltranferase (LCAT) activation. Dimyristoyl phosphatidylcholine (DMPC) binding studies revealed slow interaction of proapoA-I(Lys107del) with DMPC relative to normal proapoA-I. After preincubation with human plasma lipoprotein (d<1.225 g/ml) for 1 h at 37 degrees C, 125I-labeled normal proapoA-I chromatographed as a single peak with the high density lipoprotein (HDL) fraction, whereas 125I-labeled proapoA-I(Lys107del) chromatographed with both HDL and free proapoA-I (26% of the radioactivity). Circular dichroism measurements showed that the alpha-helical content of lipid-bound proapoA-I (Lys107del) was reduced to 64 versus 73% of normal proapoA-I. Non-denaturing gradient gel electrophoresis of reconstituted HDL assembled with either proapoA-I(Lys107del) or normal proapoA-I showed that the mutation led to the formation of a second population of smaller rHDL particles. DMPC/proapoA-I(Lys107del) and normal DMPC/proapoA-I complexes exhibited a similar capacity to promote cholesterol efflux from fibroblasts. ProapoA-I (Lys107del) also activated LCAT similar to wild type proapoA-I and human plasma apoA-I. We conclude that deletion of Lys 107 substantially alters the lipid binding properties of the protein, which correlated with reduced binding to plasma HDL in vitro, but did not affect the capacity of the mutant/lipid complex to promote cholesterol efflux or activate LCAT.
authors.affiliation: Department of Internal Medicine, Fukuoka University, School of Medicine, 45-1, 7-chome Nanakuma, Jonan-ku, 814-80, Fukuoka, Japan.
authors.forename: W
authors.initials: W
authors.lastname: Huang
authors.forename: A
authors.initials: A
authors.lastname: Matsunaga
authors.forename: W
authors.initials: W
authors.lastname: Li
authors.forename: H
authors.initials: H
authors.lastname: Han
authors.forename: A
authors.initials: A
authors.lastname: Hoang
authors.forename: M
authors.initials: M
authors.lastname: Kugi
authors.forename: T
authors.initials: T
authors.lastname: Koga
authors.forename: D
authors.initials: D
authors.lastname: Sviridov
authors.forename: N
authors.initials: N
authors.lastname: Fidge
authors.forename: J
authors.initials: J
authors.lastname: Sasaki
mesh_terms: D016632:Apolipoprotein A-I / Q000378:metabolism; D001054:Apolipoproteins A / Q000235:genetics* / Q000378:metabolism*; D002478:Cells, Cultured; D002784:Cholesterol / Q000378:metabolism; D002942:Circular Dichroism; D004134:Dimyristoylphosphatidylcholine / Q000378:metabolism; D004789:Enzyme Activation; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism*; D008075:Lipoproteins, HDL / Q000378:metabolism*; D008239:Lysine / Q000235:genetics; D009154:Mutation; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000378:metabolism; D011498:Protein Precursors / Q000235:genetics* / Q000378:metabolism*; D011994:Recombinant Proteins / Q000378:metabolism
chemical_list: D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D011498:Protein Precursors; D011994:Recombinant Proteins; D002784:Cholesterol; D007862:Phosphatidylcholine-Sterol O-Acyltransferase; D008239:Lysine; D004134:Dimyristoylphosphatidylcholine